english

Liste des publications

Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors. EMBO Mol Med. 2017 Dec 6. pii: e201708076. doi: 10.15252/emmm.201708076. [Epub ahead of print]

 

Calvayrac O, Mazières J, Figarol S, Marty-Detraves C, Raymond-Letron I, Bousquet E, Farella M, Clermont-Taranchon E, Milia J, Rouquette I, Guibert N, Lusque A, Cadranel J, Mathiot N, Savina A, Pradines A, Favre G. The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism. EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm. 201606646.

 

Casas-Tintó S, Maraver A, Serrano M, Ferrús A. Troponin-I enhances and is required for oncogenic overgrowth. Oncotarget. 2016 Jul 15.  [Epub ahead of print]

 

Pujol JL.Is Weight Loss a Loss of Chance in Patients Receiving Chemoradiotherapy? J Thorac Oncol. 2016 Jun;11(6):787-8.

 

Rivera-Torres J, Guzman G, Villa-Bellosta R, Orbe J, González-Gómez C, Serrano M, Díez J, Andres V & Maraver A. Targeting ?-secretases protects against angiotensin II-induced cardiac hypertrophy. Journal of Hypertension. 33, 843-850 (2015). #corresponding author.


Fernandez-Marcos PJ, Serrano M & Maraver A. Bladder cancer and the Notch pathway. Oncotarget (2015) Jan 26 [Epub ahead of print] #corresponding author


Maraver A, Fernandez-Marcos PJ, Cash T, Mendez M, Dueñas M, Maietta P, Muñoz-Martin M, Martínez-Fernández M, Canamero M, Valencia A, Grivas, D, de la Pompa JL, Paramio JM, Real FX, Serrano M. NOTCH deficiency promotes bladder cancer. Journal of Clinical Investigation. 125, 824-30 (2015). #corresponding author.


Xiong H, Maraver A, Latkowski JA, Gobert M, Shen S, Henderson T, Furtado G, Lira S, Parkhurst CN, Schlessinger K, Shen J, Tadokoro C, Ding Y, Lobry C, Trimarchi T, Aifantis I & Lafaille JJ. Characterization of two distinct lymphoproliferative diseases caused by ectopic expression of the Notch ligand DLL4 in mice. PlosOne 8, e84841 (2013). *Equally contributed to the work. #corresponding author.


Frémin C, Courcelles M, Voisin L, Lemieux S, Meloche S & Thibault P. Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. Mol Syst Biol 9, 669 (2013).


Muñoz-Espín D, Cañamero M, Maraver A, Contreras J, Murillo-Cuesta S, Varela-Nieto I, Ruberte J, Collado M & Serrano M. Programmed cell senescence during embryonic development. Cell 155, 1104-18 (2013).


Maraver A, & Serrano M#. Notching up a new therapeutic strategy for Non-Small Cell Lung Carcinoma (NSCLC). Oncotarget 3, 917-918 (2012). #corresponding author.


Herranz D, Maraver A, Canamero M, Gomez-Lopez G, Inglada-Perez L, Robledo M, Matias-Guiu X & Serrano M. Sirt1 promotes thyroid carcinogenesis driven by Pten deficiency. Oncogene 32, 4052-6 (2013). *Equally contributed to the work.


Maraver A, Herranz D, Munoz-Martin M, Gomez-Lopez G, Canamero M, Mulero F, Megias D, Sanchez-Carbayo M, Shen J, Sanchez-Cespedes M, Palomero T, Ferrando A & Serrano M#. Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell 22, 222-34 (2012). #corresponding author.


Bornachea O, Santos M, Martínez-Cruz AB, García-Escudero R, Dueñas M, Costa C, Segrelles C, Lorz C, Buitrago A, Saiz-Ladera C, Aguirre X, Grande T, Maraver A, Ariza JM, Prosper F, Serrano M, Sánchez-Céspedes M & Paramio JM. EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumors. Scientific Reports 2, 434 (2012).

Frémin C & Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 3, 8 (2010).


Matheu A, Maraver A, Collado M, Garcia-Cao I, Canamero M, Borras C, Flores JM, Klatt P, Viña J & Serrano M. Anti-aging activity of the Ink4/Arf locus. Aging Cell 8, 152-161 (2009).


Bousquet E., Mazières J., Privat M.,  Rizzati V., Casanova A., Ledoux A., Mery E., Couderc B., Favre G. & Pradines A. Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of Akt1. Cancer Research 69, 6092-9 (2009).


Frémin C, Bessard A, Ezan F, Gailhouste L, Régeard M, Le Seyec, Gilot , Pagès G, Pouysségur J, Langouët S & Baffet G. Multiple division cycles and long-term survival of hepatocytes are distingly regulated by extracellular signal-regulated kinases ERK1 and ERK2. Hepatology 49, 930-9 (2009).


Matheu A, Maraver A & Serrano M. The Arf/p53 pathway in cancer and aging. Cancer Res 68, 6031-6034 (2008).


Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borras C, Matheu A, Klatt P, Flores JM, Vina J, Serrano M & Blasco MA. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 135, 609-622 (2008).


Matheu A*, Maraver A*, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Viña J, Blasco MA & Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448, 375-379 (2007). * Equally contributed to the work.


Maraver A, Tadokoro CE, Badura ML, Shen J, Serrano M & Lafaille JJ. Effect of presenilins in the apoptosis of thymocytes and homeostasis of CD8+ T cells. Blood 110, 3218-3225 (2007).


Frémin C, Ezan F, Boisselier P, Bessard A, Pagès G, Pouysségur J & Baffet G. ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes. Hepatology 45, 1035-45 (2007).


Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, Lafaille JJ & Dustin ML. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 66, 505-511 (2006).

 

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Conception : ID Alizés